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ABBREVIATIONS
AB-PAS = Alcian blue periodic acid Schiff stain
BE = Barrett`s oesophagus
Carditis (junctitis) = Chronic inflammation in biopsy specimens obtained
immediately distal to normal appearing squamocolumnar junction
GORD = Gastro-oesophageal reflux disease
H & E =Hematoxylin and eosin stain
H2RA = Histamine2 -receptor blocking agent
IM = Intestinal metaplasia
Junctional IM = Intestinal metaplasia in biopsy specimens obtained immediately
distal to normal appearing squamocolumnar junction
Junctional SCE (JSCE) = Specialized columnar epithelium (incomplete
intestinal metaplasia) in biopsy specimens obtained immediately distal to normal
appearing squamocolumnar junction
NSAID = Nonsteroidal anti-inflammatory drug
PPI = Proton pump inhibitor
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INTRODUCTION
Gastro-oesophageal reflux disease (GORD) encompasses a spectrum of disor-
ders in which the upward reflux of gastric contents to the oesophagus causes
symptoms and/or damage to the oesophageal mucosa. GORD is a chronic dis-
ease causing longstanding morbidity (1, 2).
Several recently published  reports indicate that chronic inflammation and in-
testinal metaplasia are common histopathological findings in biopsy specimens
obtained immediately distal to normal-appearing gastro-oesophageal junction
(3-5). At present, the clinical significance of these histopathological lesions
remains obscure: some have found chronic cardia inflammation and intestinal
metaplasia to associate with GORD (6-8), while others consider these lesions
as a manifestation of Helicobacter pylori (H pylori ) infection and multifocal
atrophic gastritis (9-12).
REVIEW OF THE LITERATURE
Definition of GORD
GORD was recently defined as follows: “the term ‘gastro-oesophageal reflux
disease’  should be used to include all individuals who are exposed to the risk
of physical complications from gastro-oesophageal reflux, or who experience
clinically significant impairment of health-related well being (quality of life)
due to reflux-related symptoms, after adequate reassurance of the benign na-
ture of their symptoms” (13).
The diagnosis of GORD is indisputable if clear-cut oesophageal mucosal breaks
are detected on upper gastrointestinal endoscopy (13). However, this endos-
copy-positive form of GORD comprises only one fourth to one half of all GORD
cases (13-15). Thus the majority of GORD patients have normal oesophageal
appearance on endoscopy, i.e. are endoscopy-negative (13). GORD symptoms
may cause significant deterioration of the quality of life comparable with symp-
tomatic ischaemic heart disease and cardiac decompensation (13,16).
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Epidemiology of GORD
Due to the lack of a strict clinically applicable definition of GORD and a gold
diagnostic standard, exact data on the incidence and prevalence of GORD are
not available (13, 17). GORD is a chronic disease with spontaneous remissions
(1, 2, 17). Based on hospitalization and death rates, its prevalence has been on
the increase while that of peptic ulcer has decreased (18).
Heartburn, the main GORD symptom,  defined as a burning sensation  behind
the sternum and radiating up to the jaws, is common in Western populations.
Up to 10-40% of the general population experience heartburn (17, 19-22), while
the prevalence of erosive oesophagitis is approximately 2% to 5%  (23). GORD
increases in prevalence after the age of 40, the peak number of cases occurring
at 60 to 70 years of age (17, 19).
Symptoms and signs of GORD
Heartburn and acid regurgitation (upward flow of gastric contents to the mouth)
are the cardinal symptoms of GORD. When oesophageal pH monitoring is
used as the standard method, the specificities of heartburn and regurgitation to
predict reflux disease are 89% and 95%, respectively (24). The sensitivity of
heartburn to predict GORD is, however, only 38% and that of regurgitation 6%
(24). Daily occurrence of heartburn and regurgitation reportedly had positive
predictive values of 59% and 66%, respectively, for GORD diagnosed by 24-
hour oesophageal pH monitoring (25).
Dysphagia means difficulty on swallowing and is usually associated with a
complication of GORD, e.g. oesophageal stricture or adenocarcinoma origi-
nating from Barrett´s oesophagus (26). Odynophagia or pain on swallowing is
probably associated with mucosal erosions  (26). No data is available on the
diagnostic accuracy of the two last-mentioned symptoms to predict GORD.
Non-cardiac chest pain (27, 28), asthma (29), pneumonia and pulmonary fi-
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brosis (26), chronic cough and hoarseness (30), and dental erosions (31) are
extraoesophageal symptoms and signs of GORD.
Pathophysiology of GORD
Transient or non-swallow-induced lower oesophageal sphincter relaxations are
the major mechanism that contribute to the pathogenesis of GORD (32, 33).
The proposed mechanism for transient lower oesophageal sphincter relaxa-
tions is that sensory signals from the receptors in the gastric cardia, pharynx,
and oesophageal body are integrated in brain stem nuclei, which, in turn, trig-
ger motor responses in the lower oesophageal sphincter, pharynx and oesopha-
geal body and selective inhibition of the crural diaphragm (33). Not all tran-
sient lower sphincter relaxations are accompanied by reflux, with different in-
vestigators reporting reflux during as many as 93% or as few as 9-15% of them
(34).Their duration usually exceeds that of swallow-induced relaxation (13).
Transient lower oesophageal sphincter relaxations account for almost all re-
flux episodes in healthy subjects and endoscopy-negative and milder oesophagi-
tis patients (Los Angeles A and B), this group accounting for about 90% of
GORD cases (13).
Permanently hypotensive lower oesophageal sphincter (resting tone below the
normal range of 10 to 30 mmHg) and hiatal hernia with abnormal gastro-
oesophageal junction anatomy and physiology play a role in the pathogenesis
of severe forms of GORD (35), although in these patients, too, lower oesopha-
geal sphincter relaxations are associated with the majority of reflux episodes
(13, 34). A large hiatal hernia results in the loss of extrinsic crural diaphragmatic
compression on the sphincter zone (13). Neither hypotensive lower oesopha-
geal sphincter nor hiatal hernia alone leads to severe oesophagitis, however,
but the two conditions interact with each other resulting in increased suscepti-
bility to reflux (34, 36). Further, about half of GORD patients have prolonged
oesophageal acid clearance (34).
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Diagnosis of GORD
Clinical presentation of GORD
Heartburn and regurgitation are the typical symptoms of GORD; they usually
occur postprandially and may be exacerbated by bending over,  recumbency or
increase in intra-abdominal pressure (34, 37). If  these symptoms dominate the
patient’s complaints, their specificity to predict GORD is high (24).
Diagnostic test with proton pump inhibitor
Giving omeprazole to patients with dyspepsia including heartburn for a one
week period has a sensitivity of 75% and specificity of 55% to diagnose GORD
defined as endoscopic erosive oesophagitis or a pathologic result in 24-hour
pH monitoring (38). GORD may be the aetiologic factor in up to half of pa-
tients with noncardiac chest pain (28). A recent report showed that in the last-
mentioned group, a one week omeprazole test (60mg daily) predicted GORD
with a sensitivity of 78.3% (95% confidence interval CI 61.4 -95.1) and
specificity of 85.7% (95% CI 67.4 -100) and resulted in a 59% reduction in the
number of diagnostic procedures (28). In the latter study, GORD was diag-
nosed by endoscopy or 24 hour oesophageal pH monitoring.
Upper gastrointestinal endoscopy
Endoscopy is recommended as the first investigation to diagnose  GORD and
grade its severity (37). Only mucosal breaks or discrete areas of erythema with
or without exudate (‘erosions‘ and ‘ulcerations‘) should be considered as reli-
able endoscopic signs of GORD, because mild non-erosive mucosal changes,
e.g. diffuse mucosal erythema and/or friability, have poor reliability for diag-
nosing GORD (39). The classical grading system for mucosal breaks is that of
Savary and Miller (40). A new classification, the  Los-Angeles classification,
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has recently been introduced, which reportedly correlates well with the sever-
ity of GORD determined clinically and by pH monitoring (39, 41). However,
up to two thirds of GORD patients have normal-appearing oesophagus on en-
doscopy, i.e. are endoscopy-negative (13).
Histology
The histologic consequences of GORD are the infiltration of oesophageal epi-
thelium by inflammatory cells (neutrophils, eosinophils and lymphocytes) and/
or the reactive epithelial changes: basal cell hyperplasia and elongation of the
papillae in the distal oesophageal squamous epithelium (42, 43, 46). The value
of histology in diagnosing endoscopy-negative GORD is limited, because these
changes are observed in the lower 2-3cm of the squamous-lined oesopheageal
mucosa in up to 50% of normal subjects (46). Further, the sensitivity of the
parameter ‘papillary length’ to predict reflux disease determined by 24-hour
pH monitoring is only 46% (47).
Nevertheless, histology is essential in diagnosing the most important compli-
cation of GORD, viz. Barrett´s oesophagus, which is characterized by the re-
placement of normal oesophageal squamous epithelium by incomplete intesti-
nal metaplasia or specialized columnar epithelium (48-50). Barrett´s oesopha-
gus is a premalignant condition that may through progressive dysplasia pro-
ceed to adenocarcinoma. Compared with the general population, patients with
Barrett’s oesophagus are at 30 to 125 times increased risk of developing oesopha-
geal adenocarcinoma (50).
24-hour oesophageal pH monitoring
At present, this test is the most accurate method to diagnose GORD. Four per-
cent of the 24-hour period spent below pH 4 is considered the best discrimina-
tor between normal subjects with physiological reflux and those with GORD
(37). Reflux episodes exceeding 5 minutes may reflect impaired oesophageal
clearance (37).
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The diagnostic accuracy of  pH recording can be improved by combining it
with a symptom index that allows comparison of the percentage of symptoms
occurring at pH below 4 with the total number of symptoms (symptom
specificity index)  (51). To optimize the interpretation of the results of pH
monitoring, a symptom sensitivity index has been developed which is defined
as the number of reflux episodes associated with symptoms divided by the
total number of reflux episodes and multiplied by 100% (52).The cutoff values
of these indices have, however, been chosen arbitrarily and some symptoms
may coincide with reflux only by chance. To overcome these limitations,
Weusten et al have developed a method using probability calculation, i.e. esti-
mation of the strength of association between symptoms and reflux episodes
by  the parameter of symptom-association probability  (53).
Using this parameter, Shi et al have shown that 12.5% of patients with heart-
burn and/or regurgitation but normal result on oesophageal pH monitoring have
nevertheless a statistically significant association between symptoms and re-
flux episodes (54). The reproducibility of pH monitoring was only 77% be-
tween two consecutive recordings (54) and is also low in patients with border-
line values on pH monitoring (55). Due to these limitations, the overall sensi-
tivity of 24-hour pH monitoring to detect GORD varies between 60% and 70%
in patients with mild oesophagitis or endoscopy-negative reflux disease, but
between 90% and 100% in those with typical heartburn and/or moderate to
severe erosive oesophagitis (37).
GORD, gastritis and H pylori infection:
an unresolved relationship
A recent summary of the studies of H pylori in GORD indicates that the infec-
tion is not significantly more prevalent in patients with GORD compared to
the general population (56). Moreover, some observations suggest that H py-
lori infection may have a protective role against GORD.  Patients with previ-
ous duodenal ulcer may have an increased risk of developing reflux oesophagitis
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after H pylori eradication (57, 58), although these observations have not been
confirmed in all studies (59). Furthermore, H pylori positive patients may have
less severe reflux disease than H pylori negative ones (60). Severe atrophic
gastritis resulting from H pylori infection may be inversely associated with
reflux oesophagitis (61), and El-Serag et al reported that chronic corpus gastri-
tis may be protective against erosive oesophagitis (62).
A recent report suggested that CagA+ H pylori strain may protect against the
development of  Barrett´s oesophagus (63), while another indicated that CagA-
strains may protect against manifest oesophagitis (64). H pylori eradication
therapy did not, however, have any impact on the relapse rate of GORD pa-
tients treated with pantoprazole for up to one year (65).
H pylori infection may  protect against GORD by several mechanisms (66).
First, H pylori generates ammonia that could decrease the corrosive potential
of gastric juice. Second, severe H pylori corpus gastritis may result in dimin-
ished acid secretion probably mediated by cytokines. In addition, H pylori in-
fection is the major aetiologic factor for multifocal atrophic gastritis and hy-
pochlorhydria (66). At present, however, the exact relation between H pylori
infection and GORD remains obscure.
Chronic inflammation and intestinal metaplasia at the
oesophagogastric junction (cardia): a manifestation of
GORD or H pylori infection?
Endoscopic and histologic appearance of the gastro-
oesophageal junction
In upper gastrointestinal endoscopy, the proximal margins of the gastric mu-
cosal folds are the landmark for indentifying the junction between oesophagus
and stomach (67, 68). The normal squamocolumnar junction locates essen-
tially at this level or within 2cm of this junction (67, 68, 82). Histologically,
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gastric cardia or junctional mucosa extends  from 0.5cm up to 4cm distally
from the junction with the stratified squamous oesophageal epithelium (69).
Approximately half the thickness of the cardia mucosa is occupied by pits or
foveolae and underlying glands. These glands are tubular or a compound of
tubulo-racemose in type, and lined with mucin-secreting cells (70-72). The
presence of occasional parietal and chief cells in otherwise typical gastric car-
dia mucosa is accepted (70).
Chronic inflammation (carditis or junctitis) and intestinal
metaplasia at normal appearing oesophagogastric junction
Normal gastric cardia is devoid of inflammation, but several recent reports
have indicated that chronic inflammation or infiltration by lymphocytes and
plasma cells of the junctional mucosa is a common finding (6-10, 12). Some-
times acute inflammatory changes (neutrophils) are observed in the gastric
cardia mucosa (46). The pathogenesis of carditis remains controversial: some
reports suggest it to be associated with H pylori infection (9, 10, 12), while
others have found carditis to be a manifestation of GORD (6-8).
Similarly to chronic inflammation, intestinal metaplasia reportedly exists at
normal appearing oesophagogastric junction (3-5, 73, 74). Like carditis, the
aetiopathogenesis of junctional intestinal metaplasia is unresolved. The clini-
cal significance of chronic cardia inflammation and intestinal metaplasia is an
intriguing question, because the incidence of adenocarcinoma at this location
is reportedly on the increase (75-78, Table 1). A strong positive association
exists between H pylori prevalence and carcinoma of the distal stomach (79),
but the prevalence of the infection is significantly lower in patients with gastric
cardia cancer compared with cancers at other gastric locations (80, 81).
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Clinically and epidemiologically, junctional and oesophageal adenocarcinoma
are different from distal gastric cancers: junctional and oesophageal adenocar-
cinoma are associated with GORD and are male-predominant diseases (50).
Barrett´s oesophagus, the best-known complication of GORD and risk factor
for oesophageal adenocarcinoma, is also male-predominant. The impact of
gastro-oesophageal junctional chronic inflammation and intestinal metaplasia
on the development of junctional adenocarcinoma remains obscure.
AIMS OF THE PRESENT STUDY
The aims of the present study were:
1. To estimate the prevalence of GORD in patients referred for upper
gastrointestinal endoscopy and to examine which demographic, clinical
and histologic variables associate with endoscopy-positive GORD
2. To examine  the prevalence of chronic inflammation (carditis or junctitis),
and intestinal metaplasia of mature and immature type at normal appear
ing squamocolumnar junction in patients referred to upper gastrointestinal
endoscopy.
22
3. To examine the relationships of carditis and junctional intestinal metapla-
sia with endoscopy-positive GORD, H pylori infection and chronic
gastritis
4. To investigate whether incomplete intestinal metaplasia at the oesophago-
gastric junction is the precursor for  classical Barrett´s oesophagus, and to
compare the prevalence of dysplasia in patients with immature intestinal
metaplasia at normal appearing squamocolumnar junction and those with
Barrett´s oesophagus.
MATERIALS AND METHODS
Patients
The original study population consisted of the 1698 consecutive  patients sent
for upper gastrointestinal endoscopy between September 1 and December 31
1996 at Jyväskylä Central Hospital, which serves a referral area of approxi-
mately 242000 inhabitants. All the patients were  white and of Finnish ethnic-
ity. The main exclusion criteria were previous gastric surgery and  H pylori
eradication therapy. The final number of patients included in the subanalyses
depended on the use of medication for symptoms attributable to the upper
gastrointestinal tract, on validity of biopsy specimens, and on additional exclu-
sion criteria required for each analysis, as follows:
In study I, 1128 patients were included. Excluded were patients with acute
gastrointestinal bleeding, anaemia, weight loss, suspected or known coeliac
disease, surveillance of Barrett´s oesophagus, surveillance of peptic ulcer, or
dysplasia at gastric mucosa as indication for endoscopy.
Study II included 1053 patients. Excluded were patients with Barrett´s oesopha-
gus and those without adequate gastric and cardia biopsy specimens.
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In study III, 1119 were included. Excluded were patients with Barrett´s oesopha-
gus and those without adequate gastric cardia biopsy specimens.
Study IV included 1058 patients with data on junctional intestinal metaplasia
subtypes. The exclusion criteria were the same as in study II.
In study V, 1059 patients were included. Excluded were patients without data
on Barrett´s oesophagus and junctional incomplete intestinal metaplasia and
those who used proton pump inhibitors (PPIs) and histamine2-receptor block-
ing agents (H2RAs) before endoscopy.
Clinical, endoscopic and histologic data were collected via non-validated struc-
tured questionnaires. The main indications for endoscopy were classified as
follows:
1. Dyspepsia and ulcer-type epigastric pain
2. Dyspepsia continuing after empirical treatment
3. Heartburn and/or regurgitation
4. Non-cardiac chest pain
5. Nausea and/or vomiting
6. Dysphagia and/or pain on swallowing
7. Unspecified
Ulcer-type abdominal pain was defined as burning or gnawing pain located in
the epigastrium. Dyspepsia was defined as other chronic/recurrent symptoms
centered in the upper abdomen: discomfort or pain not typical of ulcer-type
pain, bloating or distension, belching, or early satiety. Heartburn was defined
as the presence of substernal burning sensation, and (acid) regurgitation as the
upward flow of bitter- or sour-tasting fluid into the throat or mouth. Dysphagia
was defined as difficulty on swallowing solid and/or liquid foods. Non-cardiac
chest pain was  defined as recurrent retrosternal pain without cardiac abnor-
mality after reasonable evaluation (clinical examination, electrocardiogram or
treadmill test). Included in the ‘unspecified’ group were patients who could not
be classified in any of the above categories.
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The duration of symptoms was classified as follows: 1. less than one week, 2.
from one week to less than one month, 3. from one month to less than six
months, 4. more than six months. The data on the use of gastrointestinal medi-
cation before endoscopy (antacids, histamine2- receptor blocking agents
[H2RAs], proton pump inhibitors [PPIs], sucralfate, misoprostol and procinetic
medication) were recorded.
Endoscopy
Upper gastrointestinal endoscopies were performed by physicians (N =23) at
Jyväskylä Central Hospital, Jokilaakso Hospital and at eight health care cen-
tres (Keuruu, Jyväskylä, Palokka, Muurame, Laukaa, Äänekoski, Karstula, Saa-
rijärvi). All participating physicians had received their endoscopy training at
university hospitals and/or at Jyväskylä Central Hospital. The details of the
endoscopic and biopsy sampling techniques were agreed before the present
study began. The clinical and endoscopic data were recorded via structured
questionnaires. Cases with gastric cardia biopsy specimens showing fundic or
gastric corpus type mucosae only were excluded from the present analysis.
During endoscopy, the proximal margin of gastric folds was identified as the
junction between tubular oesophagus and stomach. The normal squamocolum-
nar junction, or Z-line, is coincident with the oesophagogastric junction, but
may in patients with hiatal hernia locate up to 2cm orally from the oesoph-
agogastric junction (67, 68, 82). The appearances of normal oesophagogastric
junction as well as columnar lined oesophagus are presented in Figure 1.
Biopsy specimens were obtained from oesophageal mucosa 2-3cm orally from
the Z-line, from junctional mucosa immediately distal to normal appearing Z-
line, and from gastric body and gastric antrum 2cm or more from the pylorus
(two biopsy specimens from each site). If gastric-type epithelium extended
circumferentially or as tongues above the oesophagogastric junction, biopsy
specimens were obtained also from this site to detect Barrett´s oesophagus.
Detection of replacement of normal stratified squamous epithelium by special-
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ized columnar epithelium (incomplete intestinal metaplasia) without the length
of the metaplastic segment being specified was considered as the diagnostic
criterion for Barrett’s oesophagus (50,67).
The presence of one or more mucosal breaks (erosions or ulcerations) in the
distal oesophagus was considered diagnostic for endoscopic erosive oesophagi-
tis. The patients with endoscopic erosive oesophagitis were classified as en-
doscopy-positive GORD patients. Patients with reflux symptoms (heartburn
and/or regurgitation) predominant for 6 months or longer but normal oesopha-
geal appearance on endoscopy were classified into the endoscopy-negative
GORD group. Hiatal hernia was identified as follows. The level of the oesopha-
geal hiatus was determined by  direct observation of its limits, and the remain-
der of the entire gastro-oesophageal vestibule intrathoracic during both inspi-
ration and expiration was considered as the diagnostic criterion for sliding hi-
atal hernia (83).
Histology
Formalin fixed biopsy specimens were embedded in paraffin and tissue sec-
tions were stained with haematoxylin and eosin (H&E), alcian blue (pH 2.5)-
periodic acid Schiff (AB-PAS) and modified Giemsa. Gastritis and H pylori
infection were classified according to the Sydney system (84). H pylori infec-
tion was examined in the tissue sections stained by modified Giemsa.
Histologic oesophagitis was defined as the infiltration of oesophageal squa-
mous epithelium by inflammatory cells (lymphocytes, neutrophils or
eosinophils) with or without reactive changes, i.e. basal cell hyperplasia and
papillary elongation (46). A basal cell thickness exceeding 15% to 25% and
papillae height of 50% to 75% of the total thickness of surface epithelium was
considered diagnostic for GORD-related reactive changes (44-46).
Complete intestinal metaplasia (type I intestinal metaplasia) was defined as
the presence of goblet cells and non-goblet columnar cells with absence of
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mucin secretion (85). Incomplete intestinal metaplasia (types II and III) or spe-
cialized columnar epithelium was defined as the presence of goblet cells and
adjacent columnar-appearing cells containing neutral and acid mucins (85, 86).
Dysplasia, when present, was graded as low-grade and high-grade (50). The grade
of dysplasia was examined by two experienced pathologists independently.
In this presentation inflammation and intestinal metaplasia immediately distal
to normal-appearing Z-line  in histologically verified gastric cardia mucosa
(71) was called oesophagogastric junctional or cardia inflammation (carditis
or junctitis) and junctional or cardia intestinal metaplasia, respectively. The
presence of occasional parietal and chief cells in otherwise normal gastric car-
dia mucosa was accepted (79). In this presentation, the term ‘junctitis’ is used
as synonym for ‘carditis’. For the diagnosis of Barrett´s oesophagus, the detec-
tion of incomplete intestinal metaplasia in biopsy specimens obtained from
columnar lined oesophagus was required. Junctional or cardia specialized co-
lumnar epithelium was defined as Barrett-type epithelium detected in biopsy
specimens immediately distal to normal appearing squamocolumnar junction.
Examples of normal gastric cardia mucosa, chronic cardia inflammation, and
intestinal metaplasia of complete and incomplete type are presented in Figure 2.
The classification of the chronic gastritis topography was based on the Sydney
classification (84) : 1. normal gastric histology (normal histologic appearance
in biopsy specimens obtained from gastric antrum and corpus), 2. antral pre-
dominant (nonatrophic) gastritis: inflammation or inflammatory activity more
severe in gastric antrum than gastric body but no gastric gland atrophy, 3. an-
tral predominant atrophic gastritis: gastric gland atrophy detected in gastric
antrum but not in corpus, 4. corpus predominant gastritis: gastric gland atro-
phy detected only in gastric corpus or nonatrophic gastritis with more severe
inflammation or inflammatory activity in corpus, 5. multifocal atrophic gastri-
tis: gastritis with gastric gland atrophy in both  gastric antrum and corpus.
The histologic data were collected via questionnaire and the pathologists par-
ticipating in the present study were trained to recognise the histologic vari-
ables described above before the present study began.
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Statistics
Statistical analyses were carried out with the software package SPSS for
WindowsTM  (SPSS Inc.). The chi-square and Fischer´s tests were used to analyze
non-continuous and the Mann-Whitney U test continuous variables. P values <
0.05 were regarded as statistically significant. Multivariate logistic regression
analysis was applied to detect independent risk and protective factors, for which
odds ratios (OR) with 95% confidence intervals (95% CI) were presented.
Ethics
This study formed part of the Endoscopy 96 study project in the Jyväskylä
Central Hospital referral area. This project was approved by the ethics com-
mittee of Jyväskylä Central Hospital. The patients gave their informed consent
before the study.
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Figure 1.
Figure 2.
Figure 1. The squamocolumnar junction
(SCJ) is the visible line between the pale
squamous epithelium and red columnar
mucosa (A). The gastro-oesophageal junc-
tion (GEJ) is the imaginary line at which
the oesophagus ends and stomach begins
and is localized at the level of proximal end
of gastric folds observed with minimal air
inflation by endoscope (A). Normally SCJ
and EGJ locate at the same level (normal
appearing SCJ, C).  Columnar lined
oesophagus (CLE) denotes the circumfer-
ential or finger-like extension of SCJ orally
from EGJ (B, D). In this presentation, the
detection of chronic inflammation and in-
testinal metaplasia in biopsy specimens
obtained immediately distal to normal ap-
pearing squamocolumnar junction (A) was
called carditis (junctitis) and junctional in-
testinal metaplasia, respectively. Cases with
incomplete intestinal metaplasia observed
in biopsy specimens obtained from colum-
nar-lined oesophagus is the diagnostic cri-
terion for Barrett’s oesophagus.
Figure 2. Normal mucosa immediately distal
to normal appearing squamocolumnar
junction resembles gastric antral mucosa
and contains mucus secreting cells that are
loosely packed with abundant lamina pro-
pria (A, haematoxylin and eosin H&E).
Chronic inflammation (‘carditis’ or
’junctitis’) is characterized by the infiltra-
tion of lamina propria by lymphocytes and
plasma cells (B, H&E).The detection of
goblet cells is the prerequisite for the diag-
nosis of intestinal metaplasia. In complete
intestinal metaplasia, goblet cells and ad-
jacent columnar-appearing cells are devoid
of AB-PAS positive mucins (C, alcian blue
[pH 2.5] - periodic acid Schiff ), whereas
the incomplete type intestinal metaplasia is
characterized by acidic and neutral mucins
stained with various tones of red and blue
by AB-PAS stain (D).
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RESULTS
GORD: demographic, endoscopic and histologic
features (I)
The occurrence of GORD
Reflux symptoms, i.e. heartburn and regurgitation,  were main the indications
for upper gastrointestinal endoscopy in 119 (18%) of the 1128 patients included
in this analysis. GORD – defined as heartburn and/or acid regurgitation lasting
at least six months and/or endoscopic erosive oesophagitis, oesophageal peptic
ulcer or stricture, or Barrett´s oesophagus – was detected  in 248 (22%) pa-
tients. The overall prevalence rate of GORD was 307 per 100000 population
per year and that of endoscopy-positive GORD cases 207/100000/year.
GORD-related findings on endoscopy
Heartburn, regurgitation and erosive oesophagitis were common in all age
groups, but the complicated forms of GORD (Barrett´s oesophagus, oesopha-
geal ulcer and stricture) affected only older age groups (Figure 3). Of the pa-
tients with GORD symptoms lasting 6 months or longer and aged under 50
years (N= 87), 57 (85%) had normal appearing oesophagus at endoscopy, one
(1%) Barrett´s oesophagus, one (1%) oesophageal stricture, and five (6%) gas-
tric and/or duodenal  ulcer (all H pylori positive). Endoscopic erosive oesophagi-
tis was the commonest single lesion detected on upper gastrointestinal endos-
copy (Table 2).
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Clinical and histologic associations of GORD
Compared with the non-GORD group (N = 880), the GORD group (N =248)
was male predominant ( male: female 1.1:1 vs. 1:1.6, p < 0.001), more often
used NSAIDs (30% vs. 15%, p < 0.001), HRA2s and PPIs (27% vs. 12%, p <
0.001) and more often had histologic oesophagitis (38% vs. 25%, p < 0.001).
The prevalence of H pylori infection was equal in both groups (40%), but chronic
gastritis was a less frequent finding in the GORD group (48% vs. 54%, p =
0.08), whereas junctional specialized columnar epithelium was commoner (13%
vs. 8%, p = 0.06). The prevalences of gastric ulcer were 4% in both groups and
those of duodenal ulcer 3% and 2% in the GORD and non-GORD group, re-
spectively.
The positive and negative predictive values of heartburn and regurgitation for
endoscopy-positive GORD were 0.37 (95% CI 0.31 - 0.44) and 0.90 (95% CI
0.88 - 0.92). The risk of the patients aged under 50 years having a major lesion
on endoscopy (Barrett´s oesophagus, peptic ulcer and gastric or oesophageal
cancer) was significantly lower compared with patients aged over 50 years
(OR 0.5, 95% CI 0.3 - 0.9).
Risk and protective factors for GORD
Multivariate analysis revealed that independent risk factors for endoscopy-posi-
tive GORD were male sex (OR 1.5, 95% CI 1.0 - 2.4) and chronic inflamma-
tion at the gastro-oesophageal junction (‘carditis’, OR 1.7, 95% CI 1.0 -3.0),
whereas chronic gastritis was protective against endoscopic erosive oesophagitis
(OR 0.3, 95% CI 0.1 - 0.7).
H pylori infection (OR 1.9, 95%CI 0.9 - 4.0), age (OR 1.0, 95% CI 1.0 - 1.0)
and junctional incomplete intestinal metaplasia (OR 1.7, 95% CI 0.9 - 3.1)
were not risk factors for endoscopy-positive GORD. The result of the
multivariate analysis to detect risk factors for GORD (both endoscopy-posi-
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tive and endoscopy-negative forms included) is presented in Table 3. Of the
histologic variables, microscopic oesophagitis and incomplete intestinal meta-
plasia at normal appearing oesophagogastric junction were risk factors for
GORD (Table 3).
Chronic inflammation at normal appearing gastro-
oesophageal junction: a manifestation of GORD or
H pylori gastritis? (II)
The prevalence, and clinical and demographic associations
of junctitis
Chronic cardia inflammation was detected in 790 (75%) of 1053 patients in-
cluded in the present analysis. Compared with the ‘non-carditis’ group, the
’carditis’ group was older: mean age  58.7 years (95% CI 57.6 - 59.9 years) vs.
52.6 years (95% CI 50.7 - 54.6 years, p < 0.001). The male to female ratio was
1:1.5 in the carditis group and 1:1.6 in the non-carditis group (p = 0.6).
Of the patients with chronic cardia inflammation, 549 (69%) had concomitant
chronic gastritis (of which 70% H pylori positive) and 241 (31%) histologically
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normal stomach. In subjects with chronic gastritis, carditis was positively as-
sociated with increasing age and H pylori infection, whereas  carditis with
normal stomach was related to endoscopic erosive oesophagitis (Table 4). In
patients with chronic gastritis and carditis, the mean age (p < 0.001) and male
to female ratio (p = 0.03) were higher than those with carditis with normal
stomach (Table 4). Both carditis with chronic gastritis and normal stomach
correlated with the use of NSAIDs and microscopic oesophagitis. Intestinal
metaplasia of the incomplete type was strongly associated with carditis both in
patients with chronic gastritis and normal stomach, whereas complete intesti-
nal metaplasia was associated with carditis only in patients with chronic gastri-
tis.
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Risk factors for carditis
Multivariate analysis revealed that in patients with chronic gastritis, H pylori
infection was the only risk factor for carditis (OR 2.9, 95% CI 1.6 - 5.0), whereas
in subjects with carditis and normal stomach endoscopic erosive oesophagitis
(OR 1.8, 95% CI 1.1 - 3.1) was the only risk factor.
Specialized columnar epithelium (SCE) at the
oesophagogastric junction: prevalence and
associations (III)
Prevalence and characteristics of junctional SCE
Of the 1119 patients included in this study, 110 (10%) harboured incomplete
intestinal metaplasia or specialized columnar epithelium at normal appearing
oesophagogastric junction. Compared with the patients without junctional SCE
(N = 1009), the junctional SCE patients were older (65.3, 95% CI 62.9 - 67.7
vs. 56.7, 95% CI 55.7 - 57.7, p < 0.001), and more often had carditis (92%
vs.73%, p < 0.001) and endoscopic erosive oesophagitis (22% vs. 13%, p =
0.01). Junctional SCE associated with antral predominant gastritis (p < 0.001),
but 8% of the junctional SCE cases were detected in subjects with histologically
normal stomach. In univariate analysis, junctional SCE was significantly asso-
ciated with corpus H pylori infection (p = 0.04), but not with antral or cardia H
pylori  infection. No male predominance was observed in junctional SCE pa-
tients (male to female ratio 1:1.1).
Risk factors for junctional SCE
Multivariate analysis revealed that independent risk factors for junctional SCE
were chronic cardia inflammation (OR 3.1, 95% CI 1.4 - 6.8), endoscopic ero-
sive oesophagitis (OR 1.8, 95% CI 1.1 - 3.1) and age (OR 1.4 per decade, 95%
CI 1.2 - 1.6), whereas the following factors were not independent risk factors:
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chronic antral (OR 1.0, 95% CI 0.5 - 2.1) and corpus (OR 0.8, 95% CI 0.4 -
1.8) gastritis, corpus H pylori infection (OR 1.4, 95% CI 0.7 - 2.8) and antral
intestinal metaplasia (OR 1.2, 95% CI 0.7 - 2.1).
Complete and incomplete intestinal metaplasia at the
oesophagogastric junction: prevalences and
associations with endoscopic erosive oesophagitis and
gastritis (IV)
Prevalence and characteristics of junctional intestinal
metaplasia subtypes
Of the 1058 patients included in this analysis, intestinal metaplasia of the com-
plete type at normal appearing squamocolumnar junction was observed in 196
(19%) patients, and in 134 (13%) it was the sole IM subtype. Incomplete
junctional IM or SCE was detected in 101 (10%) patients, of whom 62 (61%)
also had the complete type IM.
The clinical, endoscopic and histologic data of patients with and without oesoph-
agogastric junctional IM are presented in Table 5. The subjects with junctional
complete and incomplete IM were older than those without either IM subtype.
Both  junctional IM subtypes  were associated with chronic cardia inflamma-
tion. The complete IM type was associated with H pylori  infection, whereas a
positive association was observed between the incomplete type IM and  endo-
scopic erosive oesophagitis (Table 5).
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Both IM types were more common in patients with chronic gastritis compared
with those with normal gastric histology. Incomplete junctional IM associated
with antral predominant atrophic gastritis, whereas the complete IM type was
associated with all subtypes of chronic gastritis (Table 6).
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Risk factors for junctional IM subtypes
Multivariate analysis revealed that age, antral predominant nonatrophic/atrophic
gastritis and multifocal atrophic gastritis were risk factors for junctional com-
plete IM, whereas age, carditis and endoscopic erosive oesophagitis were risk
factors for incomplete intestinal metaplasia (Table 7). H pylori infection was
not an independent risk factor for either junctional IM subtype.
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Classical Barrett’s oesophagus contrasted with Barrett-
type columnar epithelium at the gastro-oesophageal
junction: demographic, endoscopic and histologic
features
Prevalences and associations
Among the 1059 patients included in this study, Barrett´s oesophagus (BE)
was observed in 25 (2%) and specialized columnar epithelium at normal ap-
pearing squamocolumnar junction without BE (junctional SCE or JSCE) in 99
(9%) patients.The mean length of  Barrett´s epithelium was 6cm (95% CI 4 -
8cm). Both BE and JSCE patients were older than those without either of these
lesions (Table 8). Endoscopic erosive oesophagitis associated with both BE
and JSCE, but only BE was a male-predominant lesion. Compared with the
non-BE non-JSCE group, chronic gastritis and H pylori infection were more
common in the JSCE group, although the differences were not statistically
significant (Table 8). In univariate analysis, a strong association between JSCE
and antral predominant atrophic gastritis was observed (V).
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Risk factors for BE and JSCE
Multivariate analysis revealed that endoscopic erosive oesophagitis and age
were  independent risk factors for both BE and JSCE.  Male sex was a risk
factor only for BE (Table 9).
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DISCUSSION
Study population
To minimize selection bias, the present study population consisted of consecu-
tive series of dyspeptic patients from a strictly defined area sent for open ac-
cess upper gastrointestinal endoscopy over a four month period. However, our
study population may not be a representative sample of all GORD and dyspep-
tic patients consulting their general practitioners. First, open-access endoscopy
is not available in all  health centres, and where it is not the threshold for
referring dyspeptic and GORD patients to endoscopy may be higher. Second,
in line with present recommendations (87, 88), young dyspeptic and GORD
patients are treated empirically without endoscopy. Heikkinen et al recently
reported (89) that approximately one fourth of patients in Finland with GORD
symptoms are referred for endoscopy.
Clinical, endoscopic and histologic data
Although the data were collected by structured questionnaires, interobserver
variation in detecting oesophageal mucosal breaks may have had an impact on
the observed prevalence rate of endoscopy-positive GORD. The agreement in
detecting mild mucosal breaks is poorer than that in detecting more severe
forms of GORD (39). Reliable data on the presence of hiatal hernia and smok-
ing habit were obtained only from a portion of the study population and their
impact on GORD-related variables could not be determined in the present study.
A further problem is the lack of universally accepted and reproducible anatomic
landmarks of normal gastro-oesophageal and squamocolumnar junction (72).
Some authors consider the location of squamocolumnar junction within 2cm
of the proximal margin of the gastric folds as normal (67, 68), while others
believe that the normal squamocolumnar junction locates at the same level as
the oesophagogastric junction or the proximal margin of the gastric folds (82).
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Squamocolumnar junction locating in the distal oesophagus orally from the
oesophagogastric junction is termed columnar-lined oesophagus and may con-
tain cardiac or fundic type mucosa, or intestinal metaplasia (72). In the present
study, cardia was defined by histological and not endoscopic criteria. Further,
only biopsy specimens showing gastric cardia mucosa and intestinal metapla-
sia at the same level were considered to represent gastric cardia inflammation
and intestinal metaplasia, respectively. The presence of occasional parietal and
chief cells in otherwise morphologically typical gastric cardia mucosa was ac-
cepted, although this interpretation is not universally recognised (72).
The prevalence of H pylori infection was assayed only by histology, which
may have underestimated its true prevalence in the present study (90). Obtain-
ing more than two biopsy specimens from gastric, junctional and oesophageal
mucosa might have yielded higher prevalences of H pylori infection, and
junctional and oesophageal intestinal metaplasia.  Indirect evidence for this is
that oesophageal specialized columnar epithelium was detected only in half of
the patients referred for endoscopy due to  Barrett´s oesophagus surveillance
(V).
Epidemiology of GORD
GORD encompasses a wide spectrum of disorders, from endoscopy-negative
cases with mild symptoms to complicated cases with oesophageal stricture,
ulcer, bleeding or  Barrett´s oesophagus (17, 91). Reliable data on the epidemi-
ology of GORD is not available due to the lack of a diagnostic gold standard
(13, 17). Further, since GORD is a chronic condition with spontaneous remis-
sions  (2, 17), it is difficult to determine the true incidence and prevalence of
the disease.
The present findings indicated that in our hospital catchment area 207 new
endoscopy-positive GORD cases per 100000 inhabitants  were detected yearly.
This figure is clearly higher than the 120 per 100000 reported from Uppsala
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County, Sweden (92). The present study revealed that of the patients with re-
flux symptoms as the indication for endoscopy, 37% had endoscopic erosive
oesophagitis. Previous studies have detected corresponding prevalence rates to
vary from 38% to 75% (91). As in most earlier studies (17, 91), endoscopic
erosive oesophagitis was here confirmed a male predominant disease.
Recent reports have indicated that about one fifth of Western populations ex-
perience heartburn and regurgitation at least weekly (20, 21). The present study
indicated that the specificity of heartburn and regurgitation to predict endos-
copy-positive GORD is high, but that their sensitivity is low. This finding ac-
cords with an earlier report on the sensitivity and specificity of these symp-
toms to predict reflux disease determined by oesophageal pH monitoring (24).
Further, the results of the present study suggest that GORD patients under 50
years of age may be treated empirically without a significant risk of missing
major diseases (e.g. cancer). The apparently conflicting finding of a positive
association between the use of PPIs and H2RAs and endoscopy-positive GORD
is explained by the fact that general practitioners refer those GORD patients
for endoscopy who have not responded adequately to medical therapy.
GORD and H pylori infection
At present, the role of H pylori infection in the pathogenesis of GORD remains
speculative. The incidence of GORD reportedly increases in duodenal ulcer pa-
tients after H pylori eradication therapy (57), although this finding has not been
confirmed in all studies (59). The prevalence of  H pylori infection does not
differ from that in the general population (56). In the present study, moreover, H
pylori prevalence was similar in patients with or without endoscopy-positive
GORD. The possible increase of gastric gland atrophy in H pylori-positive GORD
patients treated with proton pump inhibitors has given rise to concern (114). A
recent report showed, however, that up to three years omeprazole treatment does
not increase the risk of developing of gastric corpus glandular atrophy and intes-
tinal metaplasia in H pylori-infected GORD patients (115).
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We observed, however, that chronic gastritis may protect against erosive
oesophagitis. Our finding is concordant with that of El-Serag et al, who re-
ported chronic corpus gastritis to reduce the risk of reflux oesophagitis by 54%
(62). These observations could be explained by the  the possible association of
multifocal atrophic gastritis with diminished gastric acid secretion (61).
The aetiology of chronic cardia inflammation
Some investigators have reported carditis to  associate with reflux disease (6-
8), while others claim it  to be a manifestation of H pylori infection (9, 10, 12).
At endoscopy, most patients with significant reflux symptoms do not have vis-
ible mucosal lesions at the distal oesophagus (15, 17). In the absence of visible
oesophageal mucosal breaks, inflammation at the distal oesophageal squamous
epithelium does not fulfil the criterion of an objective marker of reflux disease
(46, 47). Carditis has been shown to associate with reflux symptoms even in
patients with endoscopically normal oesophagus (8). Transient lower oesopha-
geal sphincter relaxations are the major pathogenic factor for the development
of reflux disease (13, 33) and subjects with carditis reveal a defective lower
oesophageal sphincter pressure and higher oesophageal acid exposure com-
pared with those without carditis (6, 7). Concordant with these reports, we
observed that carditis is an independent risk factor for GORD determined by
24-hour oesophageal pH monitoring (116).
Based on the present and some previous studies (9, 10), it may be concluded
that in subjects with H pylori-positive gastritis, carditis cannot serve as a marker
of reflux disease but is linked to gastritis, whereas in patients with histologically
normal stomach carditis may be a manifestation of GORD.
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Intestinal metaplasia at the normal appearing
squamocolumnar junction
Several groups have shown that intestinal metaplasia at normalappearing
oesophagogastric junction is a common finding (3-5, 73). Concordant with
these reports, approximately one fourth of our patients had intestinal metapla-
sia at the oesophagogastric junction; the incomplete type IM was detected in
10%. A summary of the above-mentioned studies is presented in Table 10.
The clinical significance of intestinal metaplasia at this location is an impor-
tant question, because this lesion is often detected in association with oesoph-
agogastric junctional adenocarcinoma (93, 94) and the incidence of these can-
cers has been on the rise (75-78). Histopathological and epidemiological fea-
tures (association with reflux disease, male predominance and increasing trend
of incidence) of oesophagogastric junctional adenocarcinoma are similar to
those of oesophageal adenocarcinoma (50, 95).  Barrett´s oesophagus is a well-
known risk factor for oesophageal adenocarcinoma (48-50), but the actual risk
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of junctional intestinal metaplasia without classical  Barrett´s oesophagus de-
veloping into dysplasia and adenocarcinoma is unknown.
The present study revealed that both complete and incomplete forms of
junctional intestinal metaplasia increase in prevalence with age and are also
detected in patients with histologically normal stomach (IV). These observa-
tions suggest that junctional intestinal metaplasia subtypes in otherwise healthy
stomach are acquired local lesions.  Although both metaplasia subtypes were
often detected simultaneously, they showed clear differences in their
pathogenesis: complete intestinal metaplasia seemed to be a manifestation of
multifocal atrophic gastritis and H pylori infection, while the incomplete form
showed marked association with endoscopy-positive GORD (IV).
Concordant with a previous report (11), dysplasia was not associated with
junctional intestinal metaplasia in the present study. The low rate of dysplasia
in junctional intestinal metaplasia subtypes suggests that the risk of these le-
sions developing into adenocarcinoma is lower than that associated with
Barrett´s oesophagus. Intestinal metaplasia at the squamocolumnar junction is,
however, a common lesion which may in  some patients progress to dysplasia
and adenocarcinoma.
Incomplete intestinal metaplasia at the
oesophagogastric junction vs. Barrett’s oesophagus
 Barrett´s oesophagus is a complication of GORD and harbours an increased
risk of oesophageal adenocarcinoma (48-50). As stated above, the histologic
hallmark of  Barrett´s oesophagus, i.e. incomplete intestinal metaplasia or spe-
cialized columnar epithelium is also detected at normal appearing oesophagogas-
tric junction without classical  Barrett´s oesophagus.
The association of GORD with incomplete intestinal metaplasia at normal-
appearing gastro-oesophageal junction without  Barrett´s oesophagus remains
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controversial (3, 4, 73, 96, 97). The present study indicated that similarly to
classical  Barrett´s oesophagus, junctional incomplete intestinal metaplasia was
associated with endoscopy-positive GORD. A recent report that junctional in-
testinal metaplasia may disappear after antireflux surgery (98) also supports
the hypothesis that junctional intestinal metaplasia results from GORD.
An important finding was the disparity in male predominance between  Barrett´s
oesophagus and junctional intestinal metaplasia  patients (V), because it sug-
gests that the latter lesion is not a direct precursor lesion for the former, or that
some male sex-linked factors are needed for junctional immature intestinal
metaplasia to develop into BE and possibly in to junctional and oesophageal
adenocarcinoma. Our observation is concordant with the report of Salo et al
(99) showing immunoreactivity for cytokeratin 13 in  Barrett´s metaplasia,
which suggests that oesophageal columnar metaplasia might arise from squa-
mous precursor cells. Further, Boch et al (100) observed a focal multilayered
epithelium that simultaneously expressed both squamous and glandular
cytokeratin markers and concluded that this multipotent cell might be the pre-
cursor for  Barrett´s epithelium.
Oesophageal adenocarcinomas develop through progressive severity of epi-
thelial dysplasia (50) in  Barrett´s metaplastic mucosa and endoscopic surveil-
lance of these patients has been recently reported to permit the detection of
oesophageal adenocarcinoma at an earlier phase and to improve postoperative
survival compared to those without surveillance (101). Encoscopic surveil-
lance with biopsy specimens is commonly recommended for patients with
Barrett´s oesophagus (49, 82, 102), although final proof that endoscopic bi-
opsy surveillance can reduce the overall mortality of oesophageal adenocarci-
noma is lacking (102, 103). Such proof is hard to obtain because the majority
of cases of   Barrett´s oesophagus remain unrecognized in the general popula-
tion (104).
Compared with  Barrett´s oesophagus, incomplete intestinal metaplasia at the
oesophagogastric junction is a far more common lesion (3-5, 73, 105) but  the
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prevalence of dysplasia in junctional SCE seems to be significantly lower than
in classical  Barrett´s oesophagus  (106, V). Thus endoscopic biopsy surveil-
lance of junctional SCE cases without dysplasia to prevent junctional cancers
may not be cost-effective.
PATIENTS WITH HEARTBURN AND/OR
REGURGITATION: WHO SHOULD BE REFERRED TO
ENDOSCOPY?
At present, oesophageal pH monitoring remains the best method to diagnose
an abnormal upward flow of acidic gastric contents to the oesophagus. How-
ever, it is time consuming, expensive and not generally available. Moreover,
even a pathological result in open-access oesophageal pH monitoring appears
not to significantly alter the treatment of GORD patients (107). The majority
of GORD cases can be diagnosed by clinical symptoms, endoscopy, histology,
and therapeutic response to PPI (108).
The proportion of the endoscopy-negative form of all GORD cases is highest
in young patients (15). The present study revealed that most new cases of BE
are diagnosed in patients referred for endoscopy for reasons other  than GORD
symptoms (V). At present, performing endoscopy on a GORD patient merely
to detect BE is not recommended (108). Although heartburn is reportedly a
risk factor for oesophageal and cardia carcinoma (110), the actual risk of a
single GORD patient having oesophageal or cardia adenocarcinoma is too low
to warrant endoscopy just to exclude these cancers (111, 112).
The drugs of choice in the treatment of GORD are proton pump inhibitors
(108).  PPIs  are superior to H2RAs (113) and also have proven efficacy in the
endoscopy-negative form of GORD (14). Further, one week omeprazole treat-
ment has a sensitivity of 75% in diagnosing GORD defined by endoscopic
erosive oesophagitis or a pathologic result in oesophageal pH monitoring (38).
A treatment test with omeprazole is reportedly useful in diagnosing GORD-
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related chest pain (28). The results of the present study (I) indicate that GORD
patients under 50 years of age seldom have any major lesions detected on en-
doscopy and may thus be treated with PPIs empirically without endoscopy.
The proposed algorithm to diagnose and treat GORD is presented in Figure 4
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RECOMMENDATIONS FOR THE ENDOSCOPY AND
SURVEILLANCE OF PATIENTS WITH JUNCTIONAL AND
OESOPHAGEAL INTESTINAL METAPLASIA
Accurate endoscopic documentation of the appearance of the oesophagus and
oesophagogastric junction is essential for the differential diagnosis of BE and
junctional SCE. The exact location of the oesophagogastric and squamoco-
lumnar junction should be measured by endoscope with the patient in left lat-
eral position using incisor teeth as the reference point. When columnar lined
oesophagus is observed, its oral extension from EGJ should be measured by
fully opened standard biopsy forceps. The measurements should be done with
the oesophagus minimally inflated and the patient holding his or her breath
after deep expiration. The best method of describing the oral extension of SCJ
(circumferential vs. finger-like) is to photograph it.
Endoscopic erosive oesophagitis should be classified according to the Los
Angeles classification, because this is the only validated method for endoscopic
grading of GORD (39, 41). In cases with severe erosive oesophagitis, the esti-
mation of the length of columnar-lined oesophagus may be difficult and should
be done only after treatment of erosive oesophagitis.
Biopsy specimens should be obtained from each quadrant with 1cm intervals
from  SCJ to EGJ. Obtaining biopsy specimens from EGJ showing typical
gastric cardia or fundic mucosa permits estimation of the whole length of the
metaplastic mucosa. Both HE and AB-PAS stain should be used, because this
combination increases the chance of detecting IM and permits the differentia-
tion of mature and immature IM subtypes (5). Patients with Barrett’s oesopha-
gus and suitable for surgery should enter regular endoscopic surveillance with
biopsy specimens. The recommended surveillance interval is two years for BE
patients without dysplasia in the metaplastic mucosa and six months for those
with low grade dysplasia, whereas those with high grade dysplasia should be
considered for surgical treatment (82).
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In patients with normal appearing  SCJ, biopsy sampling immediately distal to
the Z-line seems essential, because detection of inflammation and intestinal
metaplasia at this location is objective evidence of GORD in patients with
histologically normal stomach (II, III, IV). Due to the low rate of dysplasia in
the junctional metaplastic mucosa (III,V,11), routine endoscopic surveillance
of these patients is not recommended. For patients with junctional intestinal
metaplasia and dysplasia, the surveillance recommendations for BE patients
with dysplasia may be applied before more exact data on the cancer risk of
junctional IM patients becomes available. By definition, cases with incom-
plete intestinal metaplasia above the oesophagogastric junction, regardless of
the length of the metaplastic segment, fulfil the diagnostic criterion for Barrett’s
oesophagus and should be considered for entry into the surveillance program.
SUMMARY
The aim of the present study was to examine the occurrence, and the demo-
graphic, clinical, and histological associations of GORD in patients referred
for upper gastrointestinal endoscopy in the Jyväskylä Central Hospital district.
Special interest was focused on the relationship of chronic inflammation and
intestinal metaplasia with GORD, H pylori infection and chronic gastritis.
In study I,  the occurrence and clinical, endoscopic and histological associa-
tions of GORD were examined. The results revealed that 207 endoscopy-posi-
tive GORD cases per 100000 inhabitants were detected yearly. GORD associ-
ated with male sex, microscopic oesophagitis and incomplete intestinal meta-
plasia at the oesophagogastric junction, whereas chronic gastritis was protec-
tive against GORD. Of the GORD patients aged under 50 years (N = 87), 57
(85%) had normal oesophageal appearance at endoscopy and none had gastric
or oesophageal cancer. The complications of GORD, i.e.  Barrett´s oesopha-
gus, oesophageal stricture and ulcer, were mainly observed in patients aged
over 50 years.
53
In study II, the clinical significance of chronic inflammation at normal appear-
ing squamocolumnar junction (carditis or junctitis) was investigated. It was
revealed that  in patients with chronic gastritis, H pylori infection was an inde-
pendent risk factor for carditis, whereas in those with normal gastric histology
endoscopy-positive GORD was the only risk factor for carditis.
In studies III and V, the prevalence of specialized columnar epithelium at en-
doscopically normal appearing squamocolumnar junction and its associations
were examined. These studies revealed that junctional SCE was commonly
detected with carditis and, like classical  Barrett´s oesophagus, it associated
with endoscopy-positive GORD. Unlike BE, junctional SCE occurred with
similar frequency in both sexes and harboured dysplasia significantly less of-
ten than BE.
In study IV, the prevalences and endoscopic and histologic associations of
junctional intestinal metaplasia of complete and incomplete types were inves-
tigated. The complete type of intestinal metaplasia at normal appearing squa-
mocolumnar junction, unlike the incomplete type, was in most cases a mani-
festation of multifocal atrophic gastritis. It may, however, occur also as an
independent localized lesion in patients with histologically normal stomach.
Dysplasia in the metaplastic junctional mucosa was not observed.
CONCLUSIONS
Heartburn and regurgitation are the second most common indication  for upper
gastrointestinal endoscopy. Endoscopy-positive GORD is, however, the com-
monest single finding in patients  referred for upper gastrointestinal endos-
copy. An overwhelming majority of patients aged under 50 years and with
heartburn and/or regurgitation have normal appearance at endoscopy, i.e. have
endoscopy-negative GORD, and may be treated without prior endoscopy.
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In patients with normal oesophageal appearance at endoscopy, chronic inflam-
mation and intestinal metaplasia at normal appearing squamocolumnar junc-
tion are common findings. In patients with normal gastric histology, these le-
sions are indirect objective markers for GORD and obtaining biopsy speci-
mens from this site is essential. Intestinal metaplasia of both complete and
incomplete type are common histological findings at normal appearing squa-
mocolumnar junction. The former type IM is in most cases a manifestation of
H pylori gastritis, whereas the latter type IM is related  to GORD.
The lack of male-predominance in patients with junctional incomplete IM sug-
gests that this lesion is not a direct precursor of  Barrett´s oesophagus or that
some male sex-related factors are needed before junctional incomplete IM may
proceed to BE and possibly adenocarcinoma.
Routine endoscopic surveillance with biopsy specimens of junctional meta-
plastic mucosa without dysplasia to prevent junctional adenocarcinoma is not
recommended.
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